Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Heather M Sonnemann"'
Autor:
Yan Zhang, Zhenglu Wang, Cassian Yee, Patrick Hwu, Chantale Bernatchez, Jason Roszik, Roland Bassett, Marie-Andree Forget, Minying Zhang, Michael A Davies, Gregory Lizee, Ling Han, Fenge Li, Ligang Deng, Kyle R Jackson, Amjad H Talukder, Arjun S Katailiha, Sherille D Bradley, Qingwei Zou, Caixia Chen, Chong Huo, Yulun Chiu, Matthew Stair, Weihong Feng, Aleksander Bagaev, Nikita Kotlov, Viktor Svekolkin, Ravshan Ataullakhanov, Natalia Miheecheva, Felix Frenkel, Yaling Wang, David Hawke, Shuo Zhou, William K Decker, Heather M Sonnemann, Xueming Du
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Background Neoantigen (NeoAg) peptides displayed at the tumor cell surface by human leukocyte antigen molecules show exquisite tumor specificity and can elicit T cell mediated tumor rejection. However, few NeoAgs are predicted to be shared between pa
Externí odkaz:
https://doaj.org/article/ac1fa606444a418b80b726080cf67799
Autor:
Heather M. Sonnemann, Barbara Pazdrak, Barbara Nassif, Yimo Sun, Lama Elzohary, Amjad H. Talukder, Arjun S. Katailiha, Krishna Bhat, Gregory Lizée
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionVestigial-like 1 (VGLL1) is a co-transcriptional activator that binds to TEA domain-containing transcription factors (TEADs). Its expression is upregulated in a variety of aggressive cancer types, including pancreatic and basal-like breas
Externí odkaz:
https://doaj.org/article/d25bbf27559a40dbbe381989efdb6b3e
Autor:
Amber J. Giles, Marsha-Kay N. D. Hutchinson, Heather M. Sonnemann, Jinkyu Jung, Peter E. Fecci, Nivedita M. Ratnam, Wei Zhang, Hua Song, Rolanda Bailey, Dionne Davis, Caitlin M. Reid, Deric M. Park, Mark R. Gilbert
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-13 (2018)
Abstract Background Corticosteroids are routinely utilized to alleviate edema in patients with intracranial lesions and are first-line agents to combat immune-related adverse events (irAEs) that arise with immune checkpoint blockade treatment. Howeve
Externí odkaz:
https://doaj.org/article/dbbd8ceab8b343afa6a998b078f2f24a
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1878:188892
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76f5f07a3c34a444e24ee3fcc5469d5f
https://doi.org/10.1016/j.bbcan.2023.188892
https://doi.org/10.1016/j.bbcan.2023.188892
Autor:
Barbara Pazdrak, Heather M. Sonnemann, Salah-Eddine Bentebibel, Barbara M. Nassif, Greg Lizee, Adi Diab
Publikováno v:
Cancer Research. 83:5079-5079
Agonistic CD40 antibodies have shown promise when used in combination with checkpoint inhibitors in clinical trials for the treatment of malignancies. However, the mechanisms driving antitumor immune responses in patients are not well understood. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0073c2b7a10c4dcdaf87cb4ca2f1078
https://doi.org/10.1158/1538-7445.am2023-5079
https://doi.org/10.1158/1538-7445.am2023-5079
Autor:
Hervé Tiriac, Heather M. Sonnemann, Ivy Lai, Jason Roszik, Christopher A. Bristow, Minying Zhang, David A. Tuveson, Patrick Hwu, Robert A. Wolff, Fenge Li, Brenda Melendez, Christine B. Peterson, Bih Fang Pan, Arjun S. Katailiha, Michael P. Kim, Cassian Yee, Amjad H. Talukder, Philip L. Lorenzi, Yulun Chiu, Anirban Maitra, Milind Javle, Scott Kopetz, Mark W. Hurd, Na Qiao, David H. Hawke, Gregory Lizée, Rebecca Davis, Elizabeth A. Mittendorf, Kyle R. Jackson, Sherille D. Bradley, Ya'an Kang, Héctor M. Alvarez
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Nature Communications
Nature Communications
Cytotoxic T lymphocyte (CTL)-based cancer immunotherapies have shown great promise for inducing clinical regressions by targeting tumor-associated antigens (TAA). To expand the TAA landscape of pancreatic ductal adenocarcinoma (PDAC), we performed ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5564e046151f65f17a494f8f54632afd
https://doaj.org/article/edce20ec2f5b48fd83a56ffb4325c6fb
https://doaj.org/article/edce20ec2f5b48fd83a56ffb4325c6fb
Autor:
Kyle R Jackson, Dinler A Antunes, Amjad H Talukder, Ariana R Maleki, Kano Amagai, Avery Salmon, Arjun S Katailiha, Yulun Chiu, Romanos Fasoulis, Maurício Menegatti Rigo, Jayvee R Abella, Brenda D Melendez, Fenge Li, Yimo Sun, Heather M Sonnemann, Vladislav Belousov, Felix Frenkel, Sune Justesen, Aman Makaju, Yang Liu, David Horn, Daniel Lopez-Ferrer, Andreas F Huhmer, Patrick Hwu, Jason Roszik, David Hawke, Lydia E Kavraki, Gregory Lizée
Publikováno v:
PNAS nexus. 1(3)
Human leukocyte antigen class I (HLA-I) molecules bind and present peptides at the cell surface to facilitate the induction of appropriate CD8+ T cell-mediated immune responses to pathogen- and self-derived proteins. The HLA-I peptide-binding cleft c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbae6063ebd0311302efc9db099ae6ed
https://pubmed.ncbi.nlm.nih.gov/36003074
https://pubmed.ncbi.nlm.nih.gov/36003074
Autor:
Yimo Sun, Kyle R. Jackson, Amjad H. Talukder, Fenge Li, Arjun S. Katailiha, Gregory Lizée, Heather M. Sonnemann
Publikováno v:
Cells, Vol 10, Iss 2379, p 2379 (2021)
Engineered T cell receptor T (TCR-T) cell therapy has facilitated the generation of increasingly reliable tumor antigen-specific adaptable cellular products for the treatment of human cancer. TCR-T cell therapies were initially focused on targeting s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1297d3efa2eea744998d8554a4e40561
https://www.mdpi.com/2073-4409/10/9/2379
https://www.mdpi.com/2073-4409/10/9/2379
Autor:
Zou Qingwei, Ling Han, William K. Decker, Chong Huo, Nikita Kotlov, Michael A. Davies, Cassian Yee, David H. Hawke, Kyle R. Jackson, Gregory Lizée, Caixia Chen, Shuo Zhou, Arjun S. Katailiha, Zhenglu Wang, Deng Ligang, Chantale Bernatchez, Amjad H. Talukder, Wang Yaling, Yulun Chiu, Minying Zhang, Natalia Miheecheva, Felix Frenkel, Matthew Stair, Yan Zhang, Weihong Feng, Jason Roszik, Xueming Du, Patrick Hwu, Aleksander Bagaev, Marie Andrée Forget, Sherille D. Bradley, Roland L. Bassett, Viktor Svekolkin, Ataullakhanov Ravshan I, Fenge Li, Heather M. Sonnemann
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
BackgroundNeoantigen (NeoAg) peptides displayed at the tumor cell surface by human leukocyte antigen molecules show exquisite tumor specificity and can elicit T cell mediated tumor rejection. However, few NeoAgs are predicted to be shared between pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::116fdd0c7589d13331b363ecec16623f
http://europepmc.org/articles/PMC8268925
http://europepmc.org/articles/PMC8268925
Publikováno v:
Cancer Immunology Research. 8:B5-B5
Glioblastoma (GBM) is a lethal brain malignancy, and standard of care only offers a modest survival benefit. Emerging evidence of immune surveillance in the brain has prompted investigation of immunotherapy as a potential treatment strategy. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f44c5036b7294f6754505946ef072b27
https://doi.org/10.1158/2326-6074.tumimm19-b5
https://doi.org/10.1158/2326-6074.tumimm19-b5